Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $44.10 Consensus Price Target from Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $44.10.

A number of analysts recently commented on the company. Wolfe Research assumed coverage on Olema Pharmaceuticals in a research report on Friday, March 27th. They set a “peer perform” rating for the company. TD Cowen reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Guggenheim reduced their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Tuesday, April 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday.

Olema Pharmaceuticals Stock Down 2.7%

Olema Pharmaceuticals stock opened at $13.68 on Friday. The stock has a market cap of $1.19 billion, a PE ratio of -6.77 and a beta of 2.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. Olema Pharmaceuticals has a one year low of $3.89 and a one year high of $36.26. The stock has a fifty day moving average of $14.91 and a 200 day moving average of $20.61.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, meeting analysts’ consensus estimates of ($0.52). As a group, sell-side analysts predict that Olema Pharmaceuticals will post -2.16 EPS for the current year.

Insider Buying and Selling

In other Olema Pharmaceuticals news, insider Shawnte Mitchell sold 25,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total value of $606,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.56% of the stock is currently owned by insiders.

Institutional Trading of Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bain Capital Life Sciences Investors LLC increased its position in Olema Pharmaceuticals by 24.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock worth $212,716,000 after buying an additional 1,664,687 shares in the last quarter. Paradigm Biocapital Advisors LP increased its position in Olema Pharmaceuticals by 11.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock worth $188,604,000 after buying an additional 750,000 shares in the last quarter. Janus Henderson Group PLC increased its position in Olema Pharmaceuticals by 5.9% in the first quarter. Janus Henderson Group PLC now owns 7,108,488 shares of the company’s stock worth $106,013,000 after buying an additional 398,294 shares in the last quarter. Siren L.L.C. increased its position in Olema Pharmaceuticals by 44.1% in the first quarter. Siren L.L.C. now owns 4,756,949 shares of the company’s stock worth $70,926,000 after buying an additional 1,456,249 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Olema Pharmaceuticals by 11.4% in the fourth quarter. Vanguard Group Inc. now owns 3,561,355 shares of the company’s stock worth $89,034,000 after buying an additional 364,035 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.